# Evaxion A/S: overview EVAX · Nasdaq · CIK 1828253 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/evax.md) · [Financials](/companies/evax/financials.md) · [Filings](/companies/evax/filings.md) · [Insiders](/companies/evax/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [0.0](/filings/0001171843-25-001916.md) | [0.1](/filings/0001171843-26-001346.md) | [3.3](/filings/0001171843-26-001346.md) | [7.5](/filings/0001171843-26-001346.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | [(30406.8%)](/filings/0001171843-26-001346.md) | [(440.6%)](/filings/0001171843-26-001346.md) | [(122.7%)](/filings/0001171843-26-001346.md) | | Net margin | % | not reported | not reported | [(30308.2%)](/filings/0001171843-26-001346.md) | [(316.0%)](/filings/0001171843-26-001346.md) | [(102.4%)](/filings/0001171843-26-001346.md) | | Diluted EPS | $ per share | [(1.26)](/filings/0001104659-24-039004.md) | [(0.98)](/filings/0001104659-24-039004.md) | [(0.81)](/filings/0001104659-24-039004.md) | not reported | not reported | | Free cash flow | $m | [(23.2)](/filings/0001104659-24-039004.md) | [(26.1)](/filings/0001171843-25-001916.md) | [(17.8)](/filings/0001171843-26-001346.md) | [(12.9)](/filings/0001171843-26-001346.md) | [(6.6)](/filings/0001171843-26-001346.md) | - Revenue. XBRL Revenue: ifrs-full:Revenue. - Gross margin (gross profit / revenue). XBRL Revenue: ifrs-full:Revenue. - Operating margin (operating income / revenue). XBRL Operating income: ifrs-full:ProfitLossFromOperatingActivities; Revenue: ifrs-full:Revenue. - Net margin (net income / revenue). XBRL Net income: ifrs-full:ProfitLossAttributableToOwnersOfParent; Revenue: ifrs-full:Revenue. - Diluted EPS. XBRL Diluted EPS: ifrs-full:DilutedEarningsLossPerShare. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: ifrs-full:CashFlowsFromUsedInOperatingActivities; Capital expenditure: ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/evax/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Merck & Co., Inc.](/funds/310158.md) | 2026-06-30 | $3.8m | 1,214,126 | | New +1,214,126 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $231.6k | 74,698 | | Unchanged | | [Rathbones Group PLC](/funds/1351991.md) | 2026-06-30 | $141.7k | 45,723 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $113.4k | 36,584 | | Added +18,811 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $104.8k | 33,800 | | Reduced −5,425 | | [Annis Gardner Whiting Capital Advisors, LLC](/funds/1998414.md) | 2026-06-30 | $93.0k | 30,000 | | Unchanged | | [J. Safra Sarasin Holding AG](/funds/1890222.md) | 2026-06-30 | $71.0k | 22,896 | | New +22,896 | | [RHUMBLINE ADVISERS](/funds/1115418.md) | 2026-06-30 | $67.7k | 21,849 | | Added +190 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $63.8k | 20,581 | | New +20,581 | | [BOOTHBAY FUND MANAGEMENT, LLC](/funds/1549230.md) | 2026-06-30 | $57.1k | 18,426 | | Unchanged | ## Recent filings [All 358 filings](/companies/evax/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-30 | 07:00 ET | [6-K](/filings/0001171843-26-006992.md) | Report of a foreign private issuer, period 2026-10-30 | 0001171843-26-006992 | | 2026-10-23 | 06:00 ET | [6-K](/filings/0001171843-26-006788.md) | Report of a foreign private issuer, period 2026-10-23 | 0001171843-26-006788 | | 2026-10-19 | 06:00 ET | [6-K](/filings/0001171843-26-006678.md) | Report of a foreign private issuer, period 2026-10-19 | 0001171843-26-006678 | | 2026-10-02 | 09:05 ET | [6-K](/filings/0001171843-26-006353.md) | Report of a foreign private issuer, period 2026-10-02 | 0001171843-26-006353 | | 2026-09-14 | 08:05 ET | [6-K](/filings/0001171843-26-006028.md) | Report of a foreign private issuer, period 2026-09-14 | 0001171843-26-006028 | | 2026-09-04 | 07:00 ET | [6-K](/filings/0001171843-26-005887.md) | Report of a foreign private issuer, period 2026-09-04 | 0001171843-26-005887 | | 2026-08-20 | 07:35 ET | [6-K](/filings/0001171843-26-005672.md) | Report of a foreign private issuer, period 2026-08-20 | 0001171843-26-005672 | | 2026-08-20 | 07:30 ET | [6-K](/filings/0001171843-26-005671.md) | Report of a foreign private issuer, period 2026-06-30 | 0001171843-26-005671 | | 2026-08-17 | 08:05 ET | [6-K](/filings/0001171843-26-005577.md) | Report of a foreign private issuer, period 2026-08-17 | 0001171843-26-005577 | | 2026-08-14 | 08:05 ET | [6-K](/filings/0001171843-26-005527.md) | Report of a foreign private issuer, period 2026-08-14 | 0001171843-26-005527 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001171843-26-001346.md), filed Mar 5, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1828253 - Tickers: EVAX - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: G7 - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 30, 2026, 07:01 ET. No prices; not investment advice.